Teva, BioSante gain nod to sell transdermal testosterone gel; Boronates deliver drugs after linking with sugar;

> Teva Pharmaceutical Industries ($TEVA) and BioSante Pharmaceuticals ($BPAX) gained FDA clearance to begin selling Bio-T-Gel, a transdermal gel treatment for men with hypogonadism, or low testosterone, Bloomberg reports. Story

> Boronates may be viable drug delivery vehicles, releasing the treatment they carry by interacting with sugars on cell membranes, scientists with the University of Wisconsin and elsewhere have found. Chemical & Engineering News describes the research in detail. Story

> Cambridge University scientists in the U.K. have developed a faster process for manufacturing microcapsules that would establish better control over when they release drugs or other substances. Story

> Arrogene NanoTechnology has raised another $600,000 in a private placement offering now worth $1.1 million. The Los Angeles startup is developing nanopolymer diagnostics and drugs for brain, breast and lung cancers. Release

> Tekmira Pharmaceutical reports that it has secured two key U.S. patents involving lipid nanoparticle delivery technology formulations and the chemical modification of siRNA to limit stimulation of the immune system. Release

> An automated on-off feature built into insulin pump systems can help reduce hypoglycemia in patients with Type 1 diabetes, according to a study conducted by researchers from the University of Colorado, Medtronic ($MDT) and elsewhere. Release

> OptiNose enlisted its first patient in a Phase III study testing an acute migraine treatment using its bidirectional technology for the intranasal drug delivery of Sumatriptan powder. Story

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.